Stocks
Mutual Funds
ETFs
Pro Tools
Terminal
WealthView
Pricing
Learn More
stocksGLENMARK
resources
GLENMARK

Glenmark Pharmaceuticals Ltd.

NSE: GLENMARK
BSE: 532296
Sector: Healthcare
Industry: Pharmaceuticals
2,223.70-41.2 (-1.82%)
8 Jul, 12:00 AM

Annual Reports and Financial Documents

Glenmark Pharmaceuticals Ltd. annual reports, quarterly results, earnings call transcripts and investor presentations. All official filings in one place.

Corporate Announcements and Regulatory Filings

Glenmark Pharmaceuticals Ltd. BSE/NSE disclosures, board meeting outcomes, insider trading notifications, acquisitions and other regulatory filings.
  • Press Release / Media Release6 Jul 2026
    Announcement under Regulation 30 (LODR)-Press Release / Media Release
    Glenmark Pharmaceuticals Inc., USA launches Olanzapine for Injection, 10 mg/vial, Single - Dose Vial
  • Press Release / Media Release2 Jul 2026
    Announcement under Regulation 30 (LODR)-Press Release / Media Release
    Glenmark advances Multi-Country Phase 3 Clinical Trial of Trastuzmab rezetecan in Platinum-Resistant Ovarian Cancer
  • General30 Jun 2026
    Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
    US FDA inspection at Company''s manufacturing facility in Goa, India
  • Analyst / Investor Meet25 Jun 2026
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
    Intimation of schedule of analyst / institutional investor meeting
  • Closure of Trading Window25 Jun 2026
    Closure of Trading Window
    Intimation of Closure of Trading Window
  • Press Release / Media Release17 Jun 2026
    Announcement under Regulation 30 (LODR)-Press Release / Media Release
    Glenmark Pharmaceuticals Inc., USA launches Methylene Blue Injection USP, 50 mg/10mL (5 mg/mL) Single-Dose vial
  • Press Release / Media Release11 Jun 2026
    Announcement under Regulation 30 (LODR)-Press Release / Media Release
    Glenmark launches Winlevi (clascoterone) 10 mg/g cream in Key European Markets for the Treatment of Acne Vulgaris
  • Press Release / Media Release5 Jun 2026
    Announcement under Regulation 30 (LODR)-Press Release / Media Release
    Glenmark Pharmaceuticals Inc., USA launches Lacosamide Injection USP, 200 mg/ 20mL (10 mg/mL), Single-Dose Vials
  • Analyst / Investor Meet1 Jun 2026
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
    We have uploaded Audio Recording of Q4 FY 2025-26 Earnings Call held on June 01, 2026 on the website of the Company.
  • Press Release / Media Release29 May 2026
    Announcement under Regulation 30 (LODR)-Press Release / Media Release
    Press Release and Management Discussion & Analysis for the Fourth Quarter ended March 31, 2026
  • General29 May 2026
    Transfer Of Company''s Nebulizer Brand
    The Board of the Company at its meeting held today has approved the transfer of the Company''s Nebulizer brands/ IP portfolio to Glenmark Healthcare Limited, a wholly owned subsidiary.
  • Change in Management29 May 2026
    Announcement under Regulation 30 (LODR)-Change in Management
    The Board at its meeting held today i.e. May 29, 2026 have approved Early Retirement of Company Secretary & Compliance Officer, Appointment of Company Secretary & Compliance Officer and ....
  • Dividend29 May 2026
    Corporate Action-Board to consider Dividend
    The Board has recommended dividend of Rs. 2.5/- per share (face value of Re. 1/- each) on the equity shares of the Company for FY 2025-26 subject to the approval of the Shareholders at ....
  • Outcome of Board Meeting29 May 2026
    Board Meeting Outcome for Audited Financial Results And Recommendation Of Final Dividend
    The Board of Directors of Glenmark Pharmaceuticals Limited considered and approved audited financial results and recommended dividend.
  • Analyst / Investor Meet29 May 2026
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
    Intimation of schedule of Analyst / Institutional Investors Meeting.
  • Reg.24(A)-Annual Secretarial Compliance26 May 2026
    Compliances-Reg.24(A)-Annual Secretarial Compliance
    Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are attaching herewith the Annual Secretarial Compliance Report for the Financial ....
  • Analyst / Investor Meet23 May 2026
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
    Enclosed please find herewith the details of Earnings Call slated for Monday, June 01, 2026 at 08:30 a.m. - 09:30 a.m. (IST) for your information and record.
  • General23 May 2026
    Settlement Agreement: Pursuant To Regulation 30 Of The SEBI (LODR) Regulations, 2015,
    Settlement Agreement: Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015
  • Press Release / Media Release20 May 2026
    Announcement under Regulation 30 (LODR)-Press Release / Media Release
    Ichnos Glenmark Innovation (IGI) Announces New Development Candidate, ISB 2301, a First-in-Class Multispecific Immune Cells Activator Targeting Solid Tumors
  • Closure of Trading Window19 May 2026
    Closure of Trading Window
    The trading window has been closed from March 31, 2026 to May 31, 2026 (both days inclusive) for the approval of Audited Financial Results for the quarter and year ended March 31, 2026

Frequently Asked Questions

Where can I download the annual report of Glenmark Pharmaceuticals Ltd.?
Annual reports of Glenmark Pharmaceuticals Ltd. are available for download in the Annual Reports and Financial Documents section of the Resources tab, organised by financial year.
Where can I find the quarterly results of Glenmark Pharmaceuticals Ltd.?
Quarterly earnings results and presentations of Glenmark Pharmaceuticals Ltd. are available in the Annual Reports and Financial Documents section of the Resources tab. Detailed financials are also in the Statements tab.
Does Glenmark Pharmaceuticals Ltd. publish earnings call transcripts?
Earnings call transcripts of Glenmark Pharmaceuticals Ltd., where available, are listed in the Annual Reports and Financial Documents section of the Resources tab.
Where can I find investor presentations of Glenmark Pharmaceuticals Ltd.?
Investor presentations and annual day presentations of Glenmark Pharmaceuticals Ltd. are listed in the Resources tab under Annual Reports and Financial Documents.
What are the recent corporate announcements of Glenmark Pharmaceuticals Ltd.?
Corporate announcements and regulatory filings of Glenmark Pharmaceuticals Ltd. as submitted to BSE and NSE are available in the Corporate Announcements and Regulatory Filings section of the Resources tab.
How do I access the regulatory filings of Glenmark Pharmaceuticals Ltd.?
Regulatory filings including board meeting outcomes, insider trading disclosures and other exchange notifications of Glenmark Pharmaceuticals Ltd. are in the Corporate Announcements and Regulatory Filings section of the Resources tab.
What is the ISIN of Glenmark Pharmaceuticals Ltd.?
The ISIN (International Securities Identification Number) of Glenmark Pharmaceuticals Ltd. is INE935A01035. This is the unique identifier used across exchanges and depositories.
On which stock exchange is Glenmark Pharmaceuticals Ltd. listed?
Glenmark Pharmaceuticals Ltd. is listed on NSE and BSE. The NSE symbol is GLENMARK and the BSE code is -.
Where can I find the shareholding pattern of Glenmark Pharmaceuticals Ltd.?
The quarterly shareholding pattern of Glenmark Pharmaceuticals Ltd. showing promoter, FII, DII, mutual fund and public holdings is available in the Shareholding Pattern section on the Overview tab.
How current is the data for Glenmark Pharmaceuticals Ltd. on Sharpely?
Share price data for Glenmark Pharmaceuticals Ltd. is updated as of 8 Jul 2026. Financial statements, shareholding and other fundamental data are updated after each quarterly disclosure.